Ocugen Concludes Dosing in Cohort 2 of the P-I/II Study Evaluating OCU410ST for Stargardt Disease
Shots:
- Ocugen has concluded the dosing in cohort 2 of the P-I/II (GARDian) study. 6 patients have been dosed so far with 3 more patients to receive high dose (cohort 3)
- The P-I/II (GARDian) study will evaluate the safety & efficacy of OCU410ST [low dose (3.75×10^10vg/mL), medium dose (7.5×10^10vg/mL), high dose (2.25×10^11vg/mL)] for the treatment of Stargardt disease with P-I being dose-ranging study and P-II being dose expansion study in adult & pediatric individuals
- The Data and Safety Monitoring Board will review 4wks. safety data next month for the medium-dose cohort before advancing to Cohort 3 (high dose). Furthermore, the study update is anticipated in Q3’24
Ref: Ocugen | Image:Ocugen
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
